Recent trends in protein and peptide drug delivery systems

Asian Journal of Pharmaceutics

Volumn 3, Issue 2, 2009, Pages 69-75

  Gupta, Himanshu ^a   Sharma, Aarti ^b  

^a HAMDARD UNIVERSITY   (India)

^b JAIPUR NATIONAL UNIVERSITY   (India)

Author keywords

Drug delivery; Peptide; Protein

Indexed keywords

AMINO ACID; CORTICOSTEROID; DOXORUBICIN; EXENDIN 4; INSULIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEPTIDE; PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN;

AMINO ACID SUBSTITUTION; CHEMICAL MODIFICATION; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG PENETRATION; DRUG STABILITY; DRUG STRUCTURE; HALF LIFE TIME; HEPATITIS C; MACROMOLECULE; METERED DOSE INHALER; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; POLYMERIZATION; PROTEIN GLYCOSYLATION; PROTEIN TRANSPORT; REVIEW;

EID: 77953416243     PISSN: 09738398     EISSN: 1998409X     Source Type: Journal    
DOI: 10.4103/0973-8398.55041     Document Type: Review

References (56)

1. Semalty A, Semalty M, Singh R, Saraf SK, Shubhini S. properties and formulation of Oral Drug Delivery Systems of Protein and Peptides. Indian Journal of Pharmaceutical Sciences 2007;69:741-747
2. Matthews DM. Intestinal absorption of peptides. Physiol Rev 1975;55:537-608.
3. Dence JE. Steroids and Peptide: Selected Chemical Aspects for Biology. Biochemistry and medicine 1980;89.
4. Nelson DL, Cox MM. Lehninger Principles of Biochemistry. 4th ed., New York: W.H. Freeman and Company: 2005. p. 85-86
5. McMartin C, Hutchinson LE, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci 1987;76:535-540
6. Donovan MD, Flynn GL, Amidon GL. Asorption of polyethylene glycols 600 through 2000: The Molecular dependence of gastrointestinal and nasal absorption. Pharm Res 1990:7:863-868
7. Maitani Y, Machida Y, Nagai T. Influence of molecular weight and charge on nasal absorption of dextran and DEAE-dextran in rabbits. Int j Pharm 1989;49:23-27
8. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Del Rev 2002;54:459-476
9. Mateo C, Lombardero J, Moreno E, Morales A, Bombino G, Coloma J, et al. Removal of amphipathic epitopes from genetically engineered antibodies: Production of modified immmunoglobulins with reduced immunogenicity. Hybridoma 2000;19:436-471
10. Lyczak JB, Morrison SL. Biological and pharmacokinetic properties of novel immunoglobulin-CD4 fusion protein. Arch Virol 1994;139:189-196
11. Syed S, Schuyler PD, Kulczycky M, Sheffield WP. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 1997;89:3242-3252
12. Bot AI, Tarara TE, Smith DJ, Bot SR, Woods CM, Weers JG. Novel lipidbased hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm Res 2000;17:275-283
13. Hutchinson FG, Furr BJ. Biodegradable polymers for controlled Particle characteristics and lung deposition patterns in a human airway replica of a dry powder formulation of polylactic acid produced using supercritical fluid technology. J Aerosol Med 2003;16:65-73.
14. Padmanabhan RV, Gudapaty R, Liener IE, Schwartz BA, Hoidal JR. Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. Am Rev Respir Dis 1985;132:164-167
15. Wagner A, Vorauer-Uhl K, Kreismayr G, Katinger H. Enhanced protein loading into liposomes by the multiple crossflow injection technique. J Liposome Res 2002;12:271-283
16. Colletier JP, Chaize B, Winterhalter M, Fournier D. Protein encapsulation in liposomes: Efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol 2002;2:9.
17. Crommelin D, Schreier H. Liposomes. In: Kreuter J, editor. Colloidal Drug Delivery Systems. New York, NY: Marcel Dekker; 1994. p. 73-190.
18. Banga A. Therapeutic Peptides and Proteins: Formulation,Processing and Delivery. Lancaster, PA: Techtomic Publishing Company Inc.; 1995.
19. Cipolla D, Farr SJ, Gonda I, Otulana B. Delivery of biologics to the lung. In: Hansel TT, Barnes PJ, editors. New Drugs for Asthma, Allergy and COPD. Prog. Respir Res Basel. Switzerland: Karger; 2001;31:20-23
20. Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radicalmediated pulmonary toxicity induced by some cationic liposomes. Pharm Res 2000;17:521-525
21. Shaji J, Patole V. Protein and Peptide Drug Delivery: Oral Approaches. Indian Journal of Pharmaceutical Sciences 2008;70:269-277
22. Available from: Http://en.wikipedia.org/wiki/PEGylation [last accessed on 2008 Sep. 19]
23. Y, Matusushima A, Hiroto M, Nishimura H, Ishii A, Ueno T, Inada Y. Pegylation of proteins and bioactive substances for medical and technical applications. Progress in Polymer Science 1998;23:1233-1271
24. Harris JM, Martin NE, Modi M. Pegylation: A novel Process for Modifying Pharmacokinetics. Clin Pharmacokinet 2001;40:539-551
25. Goodson RJ, Katre NV. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology 1990;8:343-346
26. Harris JM, Martin NE, Modi M. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-551
27. Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: A new frontier in cancer chemotherapy. J chemother 2004;16:94-97
28. Al-Tabakha MM, Arida AI. Recent Challenges in Insulin Delivery Systems: A Review. Indian Journal of Pharmaceutical Sciences 2008;70:278-286
29. Malik DK, Baboota S, Ahuja A, Hasan S, Ali J. Recent Advances in Protein and Peptide Drug Delivery Systems. Curr Drug Deliv 2007;4:141-151
30. Brown L, Rashba-Step J, Scott T, et al. Pulmonary delivery of novel insulin microspheres. In: Dalby R, Byron PR, Peart J, Farr SJ, editors. Respiratory Drug Delivery XIII. Raleigh. NC: Davis Horwood International Publishing; 2002. p. 431-433
31. Fiegel J, Ehrhardt C, Schaefer UF, Lehr CM, Hanes J. Large porous particle impingement on lung epithelial cell monolayers-toward improved particle characterization in the lung. Pharm Res 2003;20:788-796
32. Evora C, Soriano I, Rogers RA, Shakesheff KN, Hanes J, Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: The effect of 1,2-dipalmitoylphosphatidylcholine. J Control Release 1998;51:143-152
33. Bittner B, Kissel T. Ultrasonic atomization for spray drying: A versatile technique for the preparation of protein loaded biodegradable microspheres. J Microencapsul 1999;16:325-341
34. Byron PR. Drug delivery devices: Issues in drug development. Proc Am Thorac Soc. 2004;1:321-328
35. st Scientific Sessions 2001.
36. Cefalu WT, Balagtas CC, Landschulz WH, Gelfand RA. Sustained efficacy and pulmonary safety of inhaled insulin during 2-years of outpatient therapy. Paper (A101) published in the American Diabetes Association'
37. Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001;134:203-207
38. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: A randomized proof-of-concept study. Lancet 2001;357:331-335
39. Rosenstock J. Mealtime rapid-acting inhaled insulin (Exubera®) improves glycemic control in patients with type 2 diabetes failing combination oral agents: A 3-month, randomized, comparative trial for the Exubera® phase III study group. Paper (A132) published in the American Diabetes Association's Diabetes Abstract Book for the 62nd Scientific Sessions. 2002.
40. Su M, Testa MA, Turner RR, Simonson DC. The relationship between regimen burden and psychological well being in persons with type 1 diabetes: Inhaled vs injectable insulin. Paper (A448) published in the American Diabetes Association's Diabetes Abstract Book for the 62nd Scientific Sessions. 2002.
41. Cappelleri JC, Gerber RA, Rosenstock J, Nadkami S, Petrie CD, Kourides IA. Relationship between improved patient satisfaction and improved glycemic control in patients with type 1 and type 2 diabetes mellitus treated with inhaled insulin: Pooled results from two multicenter randomized controlled trials. Paper (A108) published in the American Diabetes Association's Diabetes Abstract Book for the 61st Scientific Sessions. 2001.
42. st Scientific Sessions. 2001.
43. Available from: Http://www.alkermes.com/products/inhaled.html
44. Rhodes WE. Pulmonary and Nasal Delivery of Protein Drugs: Advanced Delivery Devices. Drug Delivery Technology 2002;2.
45. Availabe from: Http://findarticles.com/p/articles/mi-m0EIN/is-1999-Feb-1/ ai-53672067. [last accessed on 2008 Sep. 19].
46. Henry RR, Mudaliar SR, Howland WC 3rd, Chu N, Kim D, An B, et al. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care 2003;26:764-769
47. Schuetz YB, Naik A, Guy RH, Kalia YN. Emerging strategies for the Transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv 2005;2:533-548
48. Benson HA. Transdermal drug delivery: Penetration enhancement techniques. Curr Drug Deliv 2005;2:23-33.
49. Scheindlin S. Transdermal drug delivery: PAST, PRESENT, FUTURE. Mol Interv 2004;4:308-312
50. Amsden BG, Goosen MF. Transdermal delivery of peptide and protein drugs: An overview. AIChE journal 2004:41:1972-1997
51. Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm 1999;184:1-6.
52. Available from :http://molinterv.aspetjournals.org/cgi/reprint/4/6/308. pdf [last accessed on 2008 Aug. 24].
53. Avaialble from:http://zosanopharma.com/index.php?option=com- contentandtask=viewandid=16andItemid=30 [last accessed on 2008 Aug. 24].
54. Matriano JA, Cormier M, Johnson J, Young WA, Buttery M, Nyam K, Daddona PE. Macroflux® microprojection array patch technology: A new and efficient approach for intracutaneous immunization. Pharm Res 2002; 19:1963-1970
55. Lin W, Cormier M, Samiee A, Griffin A, Johnson B, Teng CL, Hardee GE, Daddona PE. Transdermal delivery of antisense oligonucleotides with microprojection patch (Macroflux®) technology. Pharm Res 2001;18:1789-1793
56. Gonjari I.D.,Kasture P.V, Karmarkar A.B., Solid in situ gelling nasal formulations: A tool for systemic drug delivery, Pharmaceutical reviews, 2007, 5(2) Available from: Http://www.pharmainfo.net/reviews/solidsitu-gelling-nasal- formulations-tool-systemic-drug-delivery.